739 related articles for article (PubMed ID: 27224873)
1. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
Tsirigotis P; Savani BN; Nagler A
Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
[TBL] [Abstract][Full Text] [Related]
2. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.
Bryan LJ; Gordon LI
Blood Rev; 2015 Jan; 29(1):25-32. PubMed ID: 25260226
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint blockade in lymphoid malignancies.
Thanarajasingam G; Thanarajasingam U; Ansell SM
FEBS J; 2016 Jun; 283(12):2233-44. PubMed ID: 26807978
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
5. Programmed death-1 checkpoint blockade in acute myeloid leukemia.
Sehgal A; Whiteside TL; Boyiadzis M
Expert Opin Biol Ther; 2015; 15(8):1191-203. PubMed ID: 26036819
[TBL] [Abstract][Full Text] [Related]
6. PD-1 /PD-L1 checkpoint in hematological malignancies.
Annibali O; Crescenzi A; Tomarchio V; Pagano A; Bianchi A; Grifoni A; Avvisati G
Leuk Res; 2018 Apr; 67():45-55. PubMed ID: 29428449
[TBL] [Abstract][Full Text] [Related]
7. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
Xia Y; Medeiros LJ; Young KH
Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
[TBL] [Abstract][Full Text] [Related]
9. Clinical Development of PD-1 Blockade in Hematologic Malignancies.
Pianko MJ; Goldberg AD; Lesokhin AM
Cancer J; 2018; 24(1):31-35. PubMed ID: 29360725
[TBL] [Abstract][Full Text] [Related]
10. Immune-Checkpoint Blockade Therapy in Lymphoma.
Kuzume A; Chi S; Yamauchi N; Minami Y
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706
[TBL] [Abstract][Full Text] [Related]
11. Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?
Ansell SM
J Oncol Pract; 2016 Feb; 12(2):101-6. PubMed ID: 26869644
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for checkpoint inhibition in hematologic malignancies.
Atanackovic D; Luetkens T
Semin Cancer Biol; 2018 Oct; 52(Pt 2):198-206. PubMed ID: 29775689
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint blockade in lymphoma.
Armand P
Hematology Am Soc Hematol Educ Program; 2015; 2015():69-73. PubMed ID: 26637703
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies.
Janakiram M; Pareek V; Cheng H; Narasimhulu DM; Zang X
Immunotherapy; 2016 Jun; 8(7):809-19. PubMed ID: 27349980
[TBL] [Abstract][Full Text] [Related]
16. Releasing the Brake on the Immune System: The PD-1 Strategy for Hematologic Malignancies.
Bryan LJ; Gordon LI
Oncology (Williston Park); 2015 Jun; 29(6):431-9. PubMed ID: 26091677
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint Inhibition in Hodgkin Lymphoma - a Review.
Bröckelmann PJ; Engert A
Oncol Res Treat; 2017; 40(11):654-660. PubMed ID: 29065424
[TBL] [Abstract][Full Text] [Related]
18. [Targeting the PD-1/PD-L1 immune checkpoint signal - a new treatment strategy for cancer].
Hamanishi J; Konishi I
Gan To Kagaku Ryoho; 2014 Sep; 41(9):1071-6. PubMed ID: 25248890
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint inhibition in pediatric hematologic malignancies.
Davis KL; Agarwal AM; Verma AR
Pediatr Hematol Oncol; 2017; 34(6-7):379-394. PubMed ID: 29190182
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]